Anti-DRAK2 antibody (ab8419)
Key features and details
- Rabbit polyclonal to DRAK2
- Suitable for: WB, ICC/IF
- Reacts with: Human
- Isotype: IgG
Get better batch-to-batch reproducibility with a recombinant antibody
- Research with confidence – consistent and reproducible results with every batch
- Long-term and scalable supply – powered by recombinant technology for fast production
- Success from the first experiment – confirmed specificity through extensive validation
- Ethical standards compliant – production is animal-free
Overview
-
Product name
Anti-DRAK2 antibody
See all DRAK2 primary antibodies -
Description
Rabbit polyclonal to DRAK2 -
Host species
Rabbit -
Tested applications
Suitable for: WB, ICC/IFmore details -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide:
CSKRFRFDDSLPNPHE
, corresponding to amino acids 351/365 of Human DRAK2. (Peptide available as ab8454.) -
Positive control
- Wholecell lysate from Jurkat cells An approximately 45 kDa band can be detected.
-
General notes
Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK-1 and RIP,are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 (for DAP kinase-related apoptosis-inducing protein kinases) (1). DRAKs contain anN-terminal kinase domain and a C-terminal regulation domain. Overexpression of DRAK2 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities. DRAK2 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C. -
Storage buffer
pH: 7.2
Preservative: 0.02% Sodium azide -
Concentration information loading...
-
Purity
Ion Exchange Chromatography -
Purification notes
DRAK2 Antibody is Ion exchange chromatography purified. -
Primary antibody notes
Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK-1 and RIP,are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 (for DAP kinase-related apoptosis-inducing protein kinases) (1). DRAKs contain anN-terminal kinase domain and a C-terminal regulation domain. Overexpression of DRAK2 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities. DRAK2 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues. -
Clonality
Polyclonal -
Isotype
IgG -
Light chain type
unknown -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Positive Controls
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab8419 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB | (1) |
1/500 - 1/1000. Detects a band of approximately 45 kDa (predicted molecular weight: 43 kDa).
|
ICC/IF |
Use a concentration of 10 µg/ml.
|
Notes |
---|
WB
1/500 - 1/1000. Detects a band of approximately 45 kDa (predicted molecular weight: 43 kDa). |
ICC/IF
Use a concentration of 10 µg/ml. |
Target
-
Function
Acts as a positive regulator of apoptosis. -
Tissue specificity
Highly expressed in placenta, lung, pancreas. Lower levels in heart, brain, liver, skeletal muscle and kidney. -
Sequence similarities
Belongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family. DAP kinase subfamily.
Contains 1 protein kinase domain. -
Post-translational
modificationsAutophosphorylated. -
Cellular localization
Nucleus. - Information by UniProt
-
Database links
- Entrez Gene: 9262 Human
- Omim: 604727 Human
- SwissProt: O94768 Human
- Unigene: 88297 Human
-
Alternative names
- DAP kinase related apoptosis inducing protein antibody
- DAP kinase related apoptosis inducing protein kinase 2 antibody
- DAP kinase-related apoptosis-inducing protein kinase 2 antibody
see all
Images
-
Lane 1 : Anti-DRAK2 antibody (ab8419) at 1 µg/ml (DRAK2 antibody)
Lane 2 : Anti-DRAK2 antibody (ab8419) at 2 µg/ml (DRAK2 antibody)
All lanes : Raji cell lysate
Predicted band size: 43 kDa -
All lanes : Anti-DRAK2 antibody (ab8419) at 1/500 dilution
Lane 1 : Jurkat whole cell lysate with absence of blocking peptide
Lane 2 : Raji whole cell lysate with absence of blocking peptide
Lane 3 : Jurkat whole cell lysate with presence of blocking peptide
Lane 4 : Raji whole cell lysate with presence of blocking peptide
Predicted band size: 43 kDa
Observed band size: 45 kDa why is the actual band size different from the predicted?
We are unsure about the nature of the 70 kDa band. However, DRAK2 is autophosphorylated and it is possible that this band corresponds to the phosphorylated form. The fact that the detection of this band is blocked by DRAK2 peptide indicates that it probably is closely related to the DRAK2 protein. -
ab8419 at 10µg/ml staining DRAK2 in Jurkat cells by ICC/IF
Protocols
Datasheets and documents
-
Datasheet download
References (0)
ab8419 has not yet been referenced specifically in any publications.